Determining the effect of Selenium supplementation on CD4+ T lymphocyte count in HIV+ patients refered to Iranian HIV/AIDS Research Center (IRCHA)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138904244380N2

Enrollment

100

Registered

2010-07-15

Start date

2011-06-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV infection. Unspecified human immunodeficiency virus [HIV] disease

Interventions

Intervention 1: Selenium gluconate 200 µgr elemental capsule once daily for 6 months. Intervention 2: Placebo capsule, with the same taste and color and size, once daily for 6 months.

Treatment - Drugs

Placebo

Selenium gluconate 200 µgr elemental capsule once daily for 6 months

Placebo capsule, with the same taste and color and size, once daily for 6 months

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Age 18-60 years, Confirmed HIV-1 infection with western blot test, receiving HAART, CD4 between 200 and 350, signing informed consent Exclusion criteria: Pregnancy, any other supplementation than Selinium, history of hypersensitivity to Selenium, unwilling to cooperate, any plan to leave Tehran during the next 9 months after beginning of the study, History of chronic kidney diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Serum Selenium level. Timepoint: Baseline and at the end of the study. Method of measurement: Atomic absorption spectrometry.;Body mass index. Timepoint: Baseline and at the end of the study. Method of measurement: weight(kg)/height(m)×height(m).;Blood hemoglobin. Timepoint: Baseline and at the end of the study. Method of measurement: CBC test.;Rate of opportunistic infections. Timepoint: Every month during the study. Method of measurement: Medical history and physical examination.	—

Measure

Time frame

Serum Selenium level. Timepoint: Baseline and at the end of the study. Method of measurement: Atomic absorption spectrometry.;Body mass index. Timepoint: Baseline and at the end of the study. Method of measurement: weight(kg)/height(m)×height(m).;Blood hemoglobin. Timepoint: Baseline and at the end of the study. Method of measurement: CBC test.;Rate of opportunistic infections. Timepoint: Every month during the study. Method of measurement: Medical history and physical examination.

—

Primary

Measure	Time frame
CD4+ T cell count. Timepoint: Baseline, every 3 months up to the end of the study. Method of measurement: flowcytometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahar yousefi

Tehran University of Medical Sciences

saharyousef@rocketmail.com+98 21 8895 3618

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026